35Pharma

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

GlaxoSmithKline (GSK, NYSE: GSK) announced a definitive agreement to acquire 35Pharma Inc., a Canada‑based clinical‑stage biopharmaceutical...